Location History:
- South San Francisco, CA (US) (2013 - 2015)
- Belmont, CA (US) (2010 - 2018)
Company Filing History:
10 out of 3,222 
3 out of 168 
1 out of 4 Years Active: 2010-2018
Title: Innovator Jennafer Dotson: Pioneering Advances in Cancer Therapeutics
Introduction: Jennafer Dotson, based in Belmont, California, stands out as a prominent figure in the field of pharmaceutical innovation. With an impressive portfolio of 10 patents, her work focuses on developing novel compounds aimed at treating various cancerous conditions, showcasing her commitment to advancing medical science.
Latest Patents: Among her recent contributions to the field are two notable patents. The first, titled "Azaindazole Compounds as Inhibitors of T790M containing EGFR Mutants," describes innovative compounds designed to inhibit T790M containing EGFR mutants. This invention also encompasses pharmaceutical compositions, preparation processes, and therapeutic uses that can significantly impact the prevention and treatment of cancer. The second patent, "Tricyclic PI3K Inhibitor Compounds and Methods of Use," discusses tricyclic compounds with anti-cancer and anti-inflammatory activities. This work outlines methods for employing these compounds for the diagnosis and treatment of various pathological conditions in mammalian cells.
Career Highlights: Dotson's career has been marked by her associations with distinguished companies such as Genentech, Inc. and F. Hoffmann-La Roche AG, where she has leveraged her innovative skills to drive significant advancements in biotechnology.
Collaborations: Throughout her professional journey, Jennafer has collaborated with esteemed colleagues, including Alan G. Olivero and Bing-Yan Zhu. These collaborations have fostered a vibrant environment for research and development, enhancing the scope of her innovative contributions.
Conclusion: Jennafer Dotson's work exemplifies the spirit of innovation within the pharmaceutical industry. Her patents not only demonstrate her technical expertise but also her dedication to improving therapeutic strategies for cancer treatment. As she continues to explore new avenues of research, Dotson undoubtedly remains a key player in the realm of medical advancements.